Vergent Bioscience Email Format

Biotechnology ResearchMinnesota, United States11-50 Employees

Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by improving the visibility of tumors.  

Vergent’s lead investigational compound, abenacianine sodium injection (VGT-309), is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating abenacianine sodium injection in lung cancer, with the potential to expand its application to a wide range of solid tumors.  

Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.

* Abenacianine sodium injection is an investigational product and has not been approved by the U.S. Food and Drug Administration (FDA) for any indication.

✕

Access Insights for Vergent Bioscience and Millions of Other Companies

Sign up for full access to Vergent Bioscience information.

Continue with GoogleContinue with Microsoft

No credit card needed

OR

Work email

Create AccountBy creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.

Sign up for free to view info

Company overview Employee directory